Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 27, 2025Indian Journal of Medical and Paediatric OncologyOpen Access

Role of Maintenance Therapy with Decitabine in Acute Myeloid Leukemia in First Remission: A Prospective Interventional Study from a Tertiary Care Center in Eastern India

View Full Paper
Ask AI
Bookmark
Share

Authors

SBSubham BhattacharyaABApurba BanerjeeTDTuphan Kanti Dolai

Discussion

Loading...

Member takes

Overview

Prospective interventional study shows decitabine improves disease-free survival and overall survival in acute myeloid leukemia patients post-remission.

Key Points

  • Decitabine maintenance therapy may improve disease-free survival by approximately 20.5 months in patients with AML after first remission.
  • At a median follow-up of 29 months, overall survival reached 27.5 months, showcasing potential benefits of maintenance therapy.
  • Seven patients experienced grade 3 adverse events, suggesting a manageable safety profile for decitabine in maintenance treatment.
  • This study highlights the importance of exploring hypomethylating agents as viable maintenance options for leukemia patients.

Cite This Study

Bhattacharya et al. (2025) studied this question.

synapsesocial.com/papers/68d7b3d4eebfec0fc52362cfhttps://doi.org/10.1055/s-0045-1811939
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparison of maintenance with decitabine or chemotherapy in a real-world cohort of patients with acute myeloid leukemia2026
  2. 2Individualized decitabine dosing for post-HSCT maintenance in MDS and secondary AML from MDS: long-term outcomes from the PODAC trial and matched controls2026
  3. 3Maintenance Therapy in Acute Myeloid Leukemia: Current Perspectives and Future Directions2026
  4. 4MRD-guided azacitidine maintenance improves outcomes in molecularly persistent pediatric core-binding factor AML: A retrospective cohort study2025
  5. 5Azacitidine as maintenance therapy in pediatric de novo acute myeloid leukemia2025